{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:18:56Z","timestamp":1791555536800,"version":"4.3.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41433-023-02718-2","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T09:02:32Z","timestamp":1694854952000},"page":"434-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-3263","authenticated-orcid":false,"given":"Imran","family":"Jawaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9289-5731","authenticated-orcid":false,"given":"Kathryn","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3227-2620","authenticated-orcid":false,"given":"Christopher J.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7402-4350","authenticated-orcid":false,"given":"Annegret","family":"Dahlmann-Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-3720","authenticated-orcid":false,"given":"Mark A.","family":"Bullimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"key":"2718_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology 2016;123:697\u2013708.","journal-title":"Ophthalmology"},{"key":"2718_CR2","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1001\/archopht.122.11.1667","volume":"122","author":"RM Siatkowski","year":"2004","unstructured":"Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS, Novack GD, et al. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol. 2004;122:1667\u201374.","journal-title":"Arch Ophthalmol"},{"key":"2718_CR3","first-page":"21","volume":"32","author":"T Fricke","year":"2019","unstructured":"Fricke T, Hurairah H, Huang Y, Ho SM. Pharmacological interventions in myopia management. Community Eye Health. 2019;32:21\u20132.","journal-title":"Community Eye Health"},{"key":"2718_CR4","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jaapos.2018.07.268","volume":"22","author":"E Mezer","year":"2018","unstructured":"Mezer E, Zloto O, Farzavandi SK, Gomez-de-Liano RM, Sprunger DT, Wygnanski-Jaffe T. Current trends to decrease myopia progression survey: an IPOSC global study. J Am Assoc Pediatr Ophthalmol Strabismus JAAPOS. 2018;22:e73.","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus JAAPOS"},{"key":"2718_CR5","first-page":"205","volume":"34","author":"NA McBrien","year":"1993","unstructured":"McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993;34:205\u201315.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","volume":"46","author":"A Upadhyay","year":"2020","unstructured":"Upadhyay A, Beuerman RW. Biological Mechanisms of Atropine Control of Myopia. Eye Contact Lens. 2020;46:129\u201335.","journal-title":"Eye Contact Lens"},{"key":"2718_CR7","first-page":"2028","volume":"41","author":"JR Phillips","year":"2000","unstructured":"Phillips JR, Khalaj M, McBrien NA. Induced myopia associated with increased scleral creep in chick and tree shrew eyes. Invest Ophthalmol Vis Sci. 2000;41:2028\u201334.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.pmbts.2015.05.005","volume":"134","author":"R Metlapally","year":"2015","unstructured":"Metlapally R, Wildsoet CF. Scleral Mechanisms Underlying Ocular Growth and Myopia. Prog Mol Biol Transl Sci. 2015;134:241\u20138.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2718_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/archopht.1979.01020010470017","volume":"97","author":"BJ Curtin","year":"1979","unstructured":"Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sclera of high myopia. An electron microscopic study. Arch Ophthalmol Chic Ill 1960. 1979;97:912\u20135.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"2718_CR10","first-page":"183","volume":"7","author":"ES Avetisov","year":"1983","unstructured":"Avetisov ES, Savitskaya NF, Vinetskaya MI, Iomdina EN. A study of biochemical and biomechanical qualities of normal and myopic eye sclera in humans of different age groups. Metab Pediatr Syst Ophthalmol. 1983;7:183\u20138.","journal-title":"Metab Pediatr Syst Ophthalmol"},{"key":"2718_CR11","first-page":"1277","volume":"15","author":"VA Barathi","year":"2009","unstructured":"Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis. 2009;15:1277\u201393.","journal-title":"Mol Vis"},{"key":"2718_CR12","first-page":"2217","volume":"39","author":"GJ Lind","year":"1998","unstructured":"Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci. 1998;39:2217\u201331.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR13","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1167\/iovs.17-22562","volume":"59","author":"BJ Carr","year":"2018","unstructured":"Carr BJ, Mihara K, Ramachandran R, Saifeddine M, Nathanson NM, Stell WK, et al. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. Invest Ophthalmol Vis Sci. 2018;59:2778\u201391.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR14","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1021\/pr500558y","volume":"13","author":"VA Barathi","year":"2014","unstructured":"Barathi VA, Chaurasia SS, Poidinger M, Koh SK, Tian D, Ho C, et al. Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics. J Proteome Res. 2014;13:4647\u201358.","journal-title":"J Proteome Res"},{"key":"2718_CR15","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1167\/iovs.18-24815","volume":"59","author":"STH Chiang","year":"2018","unstructured":"Chiang STH, Chen TL, Phillips JR. Effect of Optical Defocus on Choroidal Thickness in Healthy Adults With Presbyopia. Invest Ophthalmol Vis Sci. 2018;59:5188\u201393.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR16","first-page":"1726","volume":"38","author":"D Marzani","year":"1997","unstructured":"Marzani D, Wallman J. Growth of the two layers of the chick sclera is modulated reciprocally by visual conditions. Invest Ophthalmol Vis Sci. 1997;38:1726\u201339.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR17","doi-asserted-by":"crossref","unstructured":"Aldakhil S The Effect of Optical Defocus on the Choroidal Thickness: A Review. Open Ophthalmol J [Internet]. 2021 Dec 28 [cited 2022 Jul 29];15. Available from: https:\/\/openophthalmologyjournal.com\/VOLUME\/15\/PAGE\/283\/FULLTEXT\/","DOI":"10.2174\/1874364102115010283"},{"key":"2718_CR18","doi-asserted-by":"publisher","first-page":"8528315","DOI":"10.1155\/2018\/8528315","volume":"2018","author":"STH Chiang","year":"2018","unstructured":"Chiang STH, Phillips JR. Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus. J Ophthalmol. 2018;2018:8528315.","journal-title":"J Ophthalmol"},{"key":"2718_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75342-9","volume":"10","author":"STH Chiang","year":"2020","unstructured":"Chiang STH, Turnbull PRK, Phillips JR. Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia. Sci Rep. 2020;10:18310.","journal-title":"Sci Rep"},{"key":"2718_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/02713680903374190","volume":"35","author":"J Tan","year":"2010","unstructured":"Tan J, Deng ZH, Liu SZ, Wang JT, Huang C. TGF-beta2 in human retinal pigment epithelial cells: expression and secretion regulated by cholinergic signals in vitro. Curr Eye Res. 2010;35:37\u201344.","journal-title":"Curr Eye Res"},{"key":"2718_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000267651","volume":"27","author":"Y Seko","year":"1995","unstructured":"Seko Y, Tanaka Y, Tokoro T. Influence of bFGF as a potent growth stimulator and TGF-beta as a growth regulator on scleral chondrocytes and scleral fibroblasts in vitro. Ophthalmic Res. 1995;27:144\u201352.","journal-title":"Ophthalmic Res"},{"key":"2718_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","volume":"237","author":"JC Yam","year":"2021","unstructured":"Yam JC, Jiang Y, Lee J, Li S, Zhang Y, Sun W, et al. The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study. Am J Ophthalmol. 2021;237:130\u20138.","journal-title":"Am J Ophthalmol"},{"key":"2718_CR23","doi-asserted-by":"crossref","unstructured":"Tian J, Wei S, Li S, An W, Bai W, Liang X, et al. The effect of atropine 0.01% eyedrops on relative peripheral refraction in myopic children. Eye Lond Engl. 2023;37:356\u201361.","DOI":"10.1038\/s41433-021-01923-1"},{"key":"2718_CR24","unstructured":"Donders FC. On the anomalies of accommodation and refraction of the eye. New Sydenham Soc. 1864;34:443\u20135."},{"key":"2718_CR25","first-page":"78","volume":"5","author":"V GALVIS","year":"2016","unstructured":"GALVIS V, TELLO A, PARRA MM, MERAYO-LLOVES J, LARREA J, JULIAN RODRIGUEZ C, et al. Topical Atropine in the Control of Myopia. Med Hypothesis Discov Innov Ophthalmol. 2016;5:78\u201388.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"2718_CR26","first-page":"214","volume":"86","author":"WBI Pollock","year":"1916","unstructured":"Pollock WBI. The Reduction of Myopia in Children of School Age *Presented to the Association of School Medical Officers of Scotland on 18th March, 1915. Glas Med J. 1916;86:214\u20139.","journal-title":"Glas Med J."},{"key":"2718_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/00007611-196209000-00011","volume":"55","author":"S Gostin","year":"1962","unstructured":"Gostin S. Prophylatic management of progressive myopia. South Med J. 1962;55:916\u201320.","journal-title":"South Med J."},{"key":"2718_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0161-6420(79)35455-0","volume":"86","author":"RH Bedrossian","year":"1979","unstructured":"Bedrossian RH. The effect of atropine on myopia. Ophthalmology 1979;86:713\u20139.","journal-title":"Ophthalmology"},{"key":"2718_CR29","first-page":"755","volume":"93","author":"RH Kennedy","year":"1995","unstructured":"Kennedy RH. Progression of myopia. Trans Am Ophthalmol Soc. 1995;93:755\u2013800.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2718_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/bjo.59.10.529","volume":"59","author":"TS Kelly","year":"1975","unstructured":"Kelly TS, Chatfield C, Tustin G. Clinical assessment of the arrest of myopia. Br J Ophthalmol. 1975;59:529\u201338.","journal-title":"Br J Ophthalmol"},{"key":"2718_CR31","first-page":"1212","volume":"1","author":"E Gruber","year":"1979","unstructured":"Gruber E. The treatment of myopia with atropine: A clinical study. Excerpta Med Int Congr Ser. 1979;1:1212\u20136.","journal-title":"Excerpta Med Int Congr Ser"},{"key":"2718_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0161-6420(84)34138-0","volume":"91","author":"RS Brodstein","year":"1984","unstructured":"Brodstein RS, Brodstein DE, Olson RJ, Hunt SC, Williams RR. The Treatment of Myopia with Atropine and Bifocals: A Long-term Prospective Study. Ophthalmology 1984;91:1373\u20138.","journal-title":"Ophthalmology"},{"key":"2718_CR33","first-page":"527","volume":"8","author":"HV Gimbel","year":"1973","unstructured":"Gimbel HV. The control of myopia with atropine. Can J Ophthalmol J Can Ophtalmol. 1973;8:527\u201332.","journal-title":"Can J Ophthalmol J Can Ophtalmol"},{"key":"2718_CR34","first-page":"180","volume":"21","author":"MY Yen","year":"1989","unstructured":"Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21:180\u20132.","journal-title":"Ann Ophthalmol"},{"key":"2718_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1999.15.85","volume":"15","author":"YF Shih","year":"1999","unstructured":"Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharm Ther. 1999;15:85\u201390.","journal-title":"J Ocul Pharm Ther"},{"key":"2718_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology 2020;127:910\u20139.","journal-title":"Ophthalmology"},{"key":"2718_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126:113\u201324.","journal-title":"Ophthalmology"},{"key":"2718_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012;119:347\u201354.","journal-title":"Ophthalmology"},{"key":"2718_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2. Ophthalmology 2016;123:391\u20139.","journal-title":"Ophthalmology"},{"key":"2718_CR40","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285\u201391.","journal-title":"Ophthalmology"},{"key":"2718_CR41","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","volume":"116","author":"L Tong","year":"2009","unstructured":"Tong L, Huang XL, Koh ALT, Zhang XE, Tan DTH, Chua WH. Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine. Ophthalmology 2009;116:572\u20139.","journal-title":"Ophthalmology"},{"key":"2718_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/jamaophthalmol.2017.6638","volume":"136","author":"MA Bullimore","year":"2018","unstructured":"Bullimore MA, Berntsen DA. Low-Dose Atropine for Myopia Control: Considering All the Data. JAMA Ophthalmol. 2018;136:303.","journal-title":"JAMA Ophthalmol"},{"key":"2718_CR43","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology 2022;129:308\u201321.","journal-title":"Ophthalmology"},{"key":"2718_CR44","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ophtha.2023.02.020","volume":"130","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA. Efficacy in Myopia Control: The Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2023;130:771\u20132.","journal-title":"Ophthalmology"},{"key":"2718_CR45","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","volume":"159","author":"KL Loh","year":"2015","unstructured":"Loh KL, Lu QS, Tan D, Chia A. Risk Factors for Progressive Myopia in the Atropine Therapy for Myopia Study. Am J Ophthalmol. 2015;159:945\u20139.","journal-title":"Am J Ophthalmol"},{"key":"2718_CR46","first-page":"07","volume":"07","author":"FF Li","year":"2021","unstructured":"Li FF, Zhang Y, Zhang X, Kei Yip BH, Tang SM, Kam KW, et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2021;07:07.","journal-title":"Ophthalmology"},{"key":"2718_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/jamaophthalmol.2020.3451","volume":"138","author":"Y Hu","year":"2020","unstructured":"Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset With Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmol. 2020;138:1129\u201334.","journal-title":"JAMA Ophthalmol"},{"key":"2718_CR48","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","volume":"90","author":"J Cooper","year":"2013","unstructured":"Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci Publ Am Acad Optom. 2013;90:1467\u201372.","journal-title":"Optom Vis Sci Publ Am Acad Optom"},{"key":"2718_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0297-y","volume":"16","author":"CY Lee","year":"2016","unstructured":"Lee CY, Sun CC, Lin YF, Lin KK. Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study. BMC Ophthalmol. 2016;16:114.","journal-title":"BMC Ophthalmol"},{"key":"2718_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10633-012-9372-8","volume":"126","author":"A Chia","year":"2013","unstructured":"Chia A, Li W, Tan D, Luu CD. Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study. Doc Ophthalmol Adv Ophthalmol. 2013;126:177\u201386.","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"2718_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/bjo.2004.045526","volume":"89","author":"CD Luu","year":"2005","unstructured":"Luu CD, Lau AMI, Koh AHC, Tan D. Multifocal electroretinogram in children on atropine treatment for myopia. Br J Ophthalmol. 2005;89:151\u20133.","journal-title":"Br J Ophthalmol"},{"key":"2718_CR52","first-page":"02","volume":"02","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for treatment of childhood myopia in India (I-ATOM): multicentric randomized trial. Ophthalmology 2021;02:02.","journal-title":"Ophthalmology"},{"key":"2718_CR53","first-page":"14","volume":"14","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;14:14.","journal-title":"Jpn J Ophthalmol"},{"key":"2718_CR54","first-page":"1535","volume":"104","author":"A Fu","year":"2020","unstructured":"Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020;104:1535\u201341.","journal-title":"Br J Ophthalmol"},{"key":"2718_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01708-2","volume":"11","author":"C Cui","year":"2021","unstructured":"Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021;11:22267.","journal-title":"Sci Rep"},{"key":"2718_CR56","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SSY Lee","year":"2022","unstructured":"Lee SSY, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001\u201312.","journal-title":"Clin Exp Ophthalmol"},{"key":"2718_CR57","doi-asserted-by":"publisher","unstructured":"Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;e232097. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2097. Epub ahead of print.","DOI":"10.1001\/jamaophthalmol.2023.2097"},{"key":"2718_CR58","unstructured":"R Handbook: What are Least Square Means? [Internet]. [cited 2023 Jun 17]. Available from: https:\/\/rcompanion.org\/handbook\/G_05.html"},{"key":"2718_CR59","unstructured":"Bausch & Lomb Incorporated. A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study) [Internet]. clinicaltrials.gov; 2021 Dec [cited 2022 Apr 24]. Report No.: NCT03942419. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03942419"},{"key":"2718_CR60","unstructured":"Vyluma, Inc. A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia [Internet]. clinicaltrials.gov; 2022 Feb [cited 2022 Apr 24]. Report No.: NCT03350620. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03350620"},{"key":"2718_CR61","unstructured":"Sydnexis, Inc. A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children [Internet]. clinicaltrials.gov; 2022 Jan [cited 2022 Apr 24]. Report No.: NCT03918915. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03918915"},{"key":"2718_CR62","unstructured":"Clinical Trials register - Search for Atropine [Internet]. [cited 2022 Feb 15]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=Atropine"},{"key":"2718_CR63","doi-asserted-by":"publisher","first-page":"756398","DOI":"10.3389\/fmed.2021.756398","volume":"8","author":"J Gan","year":"2022","unstructured":"Gan J, Li SM, Wu S, Cao K, Ma D, He X, et al. Varying Dose of Atropine in Slowing Myopia Progression in Children Over Different Follow-Up Periods by Meta-Analysis. Front Med. 2022;8:756398.","journal-title":"Front Med"},{"key":"2718_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01746-w","volume":"20","author":"C Zhao","year":"2020","unstructured":"Zhao C, Cai C, Ding Q, Dai H. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis. BMC Ophthalmol. 2020;20:478.","journal-title":"BMC Ophthalmol"},{"key":"2718_CR65","unstructured":"Bullimore MA, Logan NS. Optical Interventions for Myopia Control. Eye Lond Engl. 2023; https:\/\/doi.org.uk\/10.1038\/s41433-023-02723-5"},{"key":"2718_CR66","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-018-0608-3","volume":"62","author":"N Kinoshita","year":"2018","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62:544\u201353.","journal-title":"Jpn J Ophthalmol"},{"key":"2718_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69710-8","volume":"10","author":"N Kinoshita","year":"2020","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:11.","journal-title":"Sci Rep"},{"key":"2718_CR68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/ICL.0000000000000746","volume":"47","author":"C Gao","year":"2021","unstructured":"Gao C, Wan S, Zhang Y, Han J. The Efficacy of Atropine Combined With Orthokeratology in Slowing Axial Elongation of Myopia Children: A Meta-Analysis. Eye Contact Lens. 2021;47:98\u2013103.","journal-title":"Eye Contact Lens"},{"key":"2718_CR69","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1120672121998903","volume":"32","author":"N Yang","year":"2022","unstructured":"Yang N, Bai J, Liu L. Low concentration atropine combined with orthokeratology in the treatment of axial elongation in children with myopia: A meta-analysis. Eur J Ophthalmol. 2022;32:221\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"2718_CR70","doi-asserted-by":"crossref","unstructured":"Zhou H, Zhao G, Li Y. Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia. Clin Exp Optom. 2022;105:520\u20136.","DOI":"10.1080\/08164622.2021.1943318"},{"key":"2718_CR71","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/opo.12722","volume":"40","author":"Q Tan","year":"2020","unstructured":"Tan Q, Ng ALK, Choy BNK, Cheng GPM, Woo VCP, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557\u201366.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2718_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/OPX.0000000000001977","volume":"100","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA. Efficacy in Myopia Control: Does Race Matter? Optom Vis Sci Publ Am Acad Optom. 2023;100:5\u20138.","journal-title":"Optom Vis Sci Publ Am Acad Optom"},{"key":"2718_CR73","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1111\/aos.14166","volume":"97","author":"M Sacchi","year":"2019","unstructured":"Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol (Copenh). 2019;97:e1136\u201340.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"2718_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00923-1","volume":"11","author":"I P\u00e9rez-Flores","year":"2021","unstructured":"P\u00e9rez-Flores I, Mac\u00edas-Murelaga B, Barrio-Barrio J. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2021;11:21748.","journal-title":"Sci Rep"},{"key":"2718_CR75","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40123-019-0194-6","volume":"8","author":"L Joachimsen","year":"2019","unstructured":"Joachimsen L, B\u00f6hringer D, Gross NJ, Reich M, Stifter J, Reinhard T, et al. A Pilot Study on the Efficacy and Safety of 0.01% Atropine in German Schoolchildren with Progressive Myopia. Ophthalmol Ther. 2019;8:427\u201333.","journal-title":"Ophthalmol Ther"},{"key":"2718_CR76","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","volume":"104","author":"A Azuara-Blanco","year":"2020","unstructured":"Azuara-Blanco A, Logan N, Strang N, Saunders K, Allen PM, Weir R, et al. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)\u2014study protocol. Br J Ophthalmol. 2020;104:950\u20135.","journal-title":"Br J Ophthalmol"},{"key":"2718_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12688\/hrbopenres.12914.1","volume":"2","author":"S McCrann","year":"2019","unstructured":"McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, et al. Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Res. 2019;2:15.","journal-title":"HRB Open Res"},{"key":"2718_CR78","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","volume":"96","author":"MA Bullimore","year":"2019","unstructured":"Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci Publ Am Acad Optom. 2019;96:463\u20135.","journal-title":"Optom Vis Sci Publ Am Acad Optom"},{"key":"2718_CR79","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1167\/iovs.13-12403","volume":"54","author":"COMET Group.","year":"2013","unstructured":"COMET Group. Myopia Stabilization and Associated Factors Among Participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54:7871\u201384.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2718_CR80","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.preteyeres.2020.100923","volume":"83","author":"NA Brennan","year":"2021","unstructured":"Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923.","journal-title":"Prog Retin Eye Res"},{"key":"2718_CR81","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/opo.12676","volume":"40","author":"CW Klaver C","year":"2020","unstructured":"Klaver C CW, Polling JR, Group EMR. Myopia management in the Netherlands. Ophthalmic Physiol Opt. 2020;40:230\u201340.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2718_CR82","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/aos.12387","volume":"92","author":"O Parssinen","year":"2014","unstructured":"Parssinen O, Kauppinen M, Viljanen A. The progression of myopia from its onset at age 8-12 to adulthood and the influence of heredity and external factors on myopic progression. A 23-year follow-up study. Acta Ophthalmol (Copenh). 2014;92:730\u20139.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"2718_CR83","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.3390\/jcm10173766","volume":"10","author":"HR Tsai","year":"2021","unstructured":"Tsai HR, Chen TL, Wang JH, Huang HK, Chiu CJ. Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis. J Clin Med. 2021;10:3766.","journal-title":"J Clin Med"},{"key":"2718_CR84","unstructured":"Wei-Lin AC. The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3) [Internet]. clinicaltrials.gov; 2017 Oct [cited 2022 Feb 16]. Report No.: NCT03140358. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03140358"},{"key":"2718_CR85","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/ijo.IJO_1462_21","volume":"70","author":"J Jethani","year":"2022","unstructured":"Jethani J. Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes. Indian J Ophthalmol. 2022;70:238\u201340.","journal-title":"Indian J Ophthalmol"},{"key":"2718_CR86","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/jop.2009.0135","volume":"26","author":"PC Fang","year":"2010","unstructured":"Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine in premyopic children. J Ocul Pharm Ther J Assoc Ocul Pharm Ther. 2010;26:341\u20135.","journal-title":"J Ocul Pharm Ther J Assoc Ocul Pharm Ther"},{"key":"2718_CR87","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","volume":"329","author":"JC Yam","year":"2023","unstructured":"Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 2023;329:472\u201381.","journal-title":"JAMA"},{"key":"2718_CR88","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","volume":"48","author":"K Richdale","year":"2022","unstructured":"Richdale K, Tomiyama ES, Novack GD, Bullimore MA. Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens. 2022;48:489\u201392.","journal-title":"Eye Contact Lens"},{"key":"2718_CR89","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/pharmaceutics12080781","volume":"12","author":"B Berton","year":"2020","unstructured":"Berton B, Chennell P, Yessaad M, Bouattour Y, Jouannet M, Wasiak M. et al. Stability of Ophthalmic Atropine Solutions for Child Myopia Control. Pharmaceutics. 2020;12:781","journal-title":"Pharmaceutics"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02718-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T13:04:31Z","timestamp":1707483871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2718"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02718-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,16]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IJ is Co-PI for Ocumension. Advisory Board Santen and Altacor. Speaker fees for Novartis and Thea Pharmaceuticals. KS has received research funding from Nevakar, Vyluma and Hoya vision. AD-N is PI NEVAKAR CHAMP, CHAMP-UK, Ocumension and Myopia-X clinical trials, Advisory boards Santen Inc, SightGlass Vision, Novartis, Thea. ECP educational events and material Santen, CooperVision, Zeiss. Parent focus groups Novartis. Mark Bullimore is a consultant for Alcon Research, Bruno vision care, CooperVision, CorneaGen, EssilorLuxottica, Eyenovia, Genentech, Johnson & Johnson Vision, Lentechs, Novartis, Oculus, Paragon Vision Sciences, and Vyluma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}